|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Katagiri S and Yamamoto M:
Multidisciplinary treatments for hepatocellular carcinoma with
major portal vein tumor thrombus. Surg Today. 44:219–226. 2014.
View Article : Google Scholar :
|
|
3
|
Santos CR and Schulze A: Lipid metabolism
in cancer. FEBS J. 279:2610–2623. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tania M, Khan MA and Song Y: Association
of lipid metabolism with ovarian cancer. Curr Oncol. 17:6–11.
2010.PubMed/NCBI
|
|
5
|
Jones SF and Infante JR: Molecular
pathways: Fatty acid synthase. Clin Cancer Res. 21:5434–5438. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chakravarthy MV, Pan Z, Zhu Y, Tordjman K,
Schneider JG, Coleman T, Turk J and Semenkovich CF: 'New' hepatic
fat activates PPARalpha to maintain glucose, lipid, and cholesterol
homeostasis. Cell Metab. 1:309–322. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kuhajda FP, Jenner K, Wood FD, Hennigar
RA, Jacobs LB, Dick JD and Pasternack GR: Fatty acid synthesis: A
potential selective target for antineoplastic therapy. Proc Natl
Acad Sci USA. 91:6379–6383. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Walter K, Hong SM, Nyhan S, Canto M,
Fedarko N, Klein A, Griffith M, Omura N, Medghalchi S, Kuhajda F,
et al: Serum fatty acid synthase as a marker of pancreatic
neoplasia. Cancer Epidemiol Biomarkers Prev. 18:2380–2385. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Witkiewicz AK, Nguyen KH, Dasgupta A,
Kennedy EP, Yeo CJ, Lisanti MP and Brody JR: Co-expression of fatty
acid synthase and caveolin-1 in pancreatic ductal adenocarcinoma:
Implications for tumor progression and clinical outcome. Cell
Cycle. 7:3021–3025. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Long QQ, Yi YX, Qiu J, Xu CJ and Huang PL:
Fatty acid synthase (FASN) levels in serum of colorectal cancer
patients: Correlation with clinical outcomes. Tumour Biol.
35:3855–3859. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cai Y, Wang J, Zhang L, Wu D, Yu D, Tian
X, Liu J, Jiang X, Shen Y, Zhang L, et al: Expressions of fatty
acid synthase and HER2 are correlated with poor prognosis of
ovarian cancer. Med Oncol. 32:3912015. View Article : Google Scholar
|
|
12
|
Vazquez-Martin A, Colomer R, Brunet J,
Lupu R and Menendez JA: Overexpression of fatty acid synthase gene
activates HER1/HER2 tyrosine kinase receptors in human breast
epithelial cells. Cell Prolif. 41:59–85. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fiorentino M, Zadra G, Palescandolo E,
Fedele G, Bailey D, Fiore C, Nguyen PL, Migita T, Zamponi R, Di
Vizio D, et al: Overexpression of fatty acid synthase is associated
with palmitoylation of Wnt1 and cytoplasmic stabilization of
beta-catenin in prostate cancer. Lab Invest. 88:1340–1348. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Benjamin DI, Li DS, Lowe W, Heuer T,
Kemble G and Nomura DK: Diacylglycerol metabolism and signaling is
a driving force underlying FASN inhibitor sensitivity in cancer
cells. ACS Chem Biol. 10:1616–1623. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Menendez JA: Fine-tuning the
lipogenic/lipolytic balance to optimize the metabolic requirements
of cancer cell growth: Molecular mechanisms and therapeutic
perspectives. Biochim Biophys Acta. 1801:381–391. 2010. View Article : Google Scholar
|
|
16
|
Zhou W, Simpson PJ, McFadden JM, Townsend
CA, Medghalchi SM, Vadlamudi A, Pinn ML, Ronnett GV and Kuhajda FP:
Fatty acid synthase inhibition triggers apoptosis during S phase in
human cancer cells. Cancer Res. 63:7330–7337. 2003.PubMed/NCBI
|
|
17
|
Winter J, Jung S, Keller S, Gregory RI and
Diederichs S: Many roads to maturity: MicroRNA biogenesis pathways
and their regulation. Nat Cell Biol. 11:228–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lin S and Gregory RI: MicroRNA biogenesis
pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pichler M and Calin GA: MicroRNAs in
cancer: From developmental genes in worms to their clinical
application in patients. Br J Cancer. 113:569–573. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hayes J, Peruzzi PP and Lawler S:
MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol
Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li X, Yang W, Lou L, Chen Y, Wu S and Ding
G: microRNA: A promising diagnostic biomarker and therapeutic
target for hepatocellular carcinoma. Dig Dis Sci. 59:1099–1107.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chang-Hao Tsao S, Behren A, Cebon J and
Christophi C: The role of circulating microRNA in hepatocellular
carcinoma. Front Biosci (Landmark Ed). 20:78–104. 2015. View Article : Google Scholar
|
|
24
|
Chen L, Lü MH, Zhang D, Hao NB, Fan YH, Wu
YY, Wang SM, Xie R, Fang DC, Zhang H, et al: miR-1207–5p and
miR-1266 suppress gastric cancer growth and invasion by targeting
telomerase reverse transcriptase. Cell Death Dis. 5:e10342014.
View Article : Google Scholar
|
|
25
|
Hao Q, Li T, Zhang X, Gao P, Qiao P, Li S
and Geng Z: Expression and roles of fatty acid synthase in
hepatocellular carcinoma. Oncol Rep. 32:2471–2476. 2014.PubMed/NCBI
|
|
26
|
Zhu X, Qin X, Fei M, Hou W, Greshock J,
Bachman KE, Wooster R, Kang J and Qin CY: Combined phosphatase and
tensin homolog (PTEN) loss and fatty acid synthase (FAS)
overexpression worsens the prognosis of Chinese patients with
hepatocellular carcinoma. Int J Mol Sci. 13:9980–9991. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gu Y, Körbel C, Scheuer C, Nenicu A,
Menger MD and Laschke MW: Tubeimoside-1 suppresses tumor
angiogenesis by stimulation of proteasomal VEGFR2 and Tie2
degradation in a non-small cell lung cancer xenograft model.
Oncotarget. 7:5258–5272. 2016.
|
|
28
|
Li H, Hu J, Wu S, Wang L, Cao X, Zhang X,
Dai B, Cao M, Shao R, Zhang R, et al: Auranofin-mediated inhibition
of PI3K/AKT/mTOR axis and anticancer activity in non-small cell
lung cancer cells. Oncotarget. 7:3548–3558. 2016.
|
|
29
|
Huang KH, Lan YT, Fang WL, Chen JH, Lo SS,
Li AF, Chiou SH, Wu CW and Shyr YM: The correlation between miRNA
and lymph node metastasis in gastric cancer. Biomed Res Int.
2015:5431632015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lü MH, Tang B, Zeng S, Hu CJ, Xie R, Wu
YY, Wang SM, He FT and Yang SM: Long noncoding RNA BC032469, a
novel competing endogenous RNA, upregulates hTERT expression by
sponging miR-1207-5p and promotes proliferation in gastric cancer.
Oncogene. Nov 9–2015.Epub ahead of print.
|
|
31
|
Qin Z, He W, Tang J, Ye Q, Dang W, Lu Y,
Wang J, Li G, Yan Q and Ma J: MicroRNAs provide feedback regulation
of epithelial-mesenchymal transition induced by growth factors. J
Cell Physiol. 231:120–129. 2016. View Article : Google Scholar
|
|
32
|
Ma R, Wang C, Wang J, Wang D and Xu J:
miRNA-mRNA interaction network in non-small cell lung cancer.
Interdiscip Sci. Apr 11–2015.Epub ahead of print. PubMed/NCBI
|
|
33
|
Gonul O, Aydin HH, Kalmis E, Kayalar H,
Ozkaya AB, Atay S and Ak H: Effects of Ganoderma lucidum (higher
Basidiomycetes) extracts on the miRNA profile and telomerase
activity of the MCF-7 breast cancer cell line. Int J Med Mushrooms.
17:231–239. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Flavin R, Peluso S, Nguyen PL and Loda M:
Fatty acid synthase as a potential therapeutic target in cancer.
Future Oncol. 6:551–562. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bhalla K, Hwang BJ, Dewi RE, Ou L, Twaddel
W, Fang HB, Vafai SB, Vazquez F, Puigserver P, Boros L, et al:
PGC1α promotes tumor growth by inducing gene expression programs
supporting lipogenesis. Cancer Res. 71:6888–6898. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang H, Feng Z, Huang R, Xia Z, Xiang G
and Zhang J: MicroRNA-449 suppresses proliferation of hepatoma cell
lines through blockade lipid metabolic pathway related to SIRT1.
Int J Oncol. 45:2143–2152. 2014.PubMed/NCBI
|
|
37
|
Huang CH, Tsai SJ, Wang YJ, Pan MH, Kao JY
and Way TD: EGCG inhibits protein synthesis, lipogenesis, and cell
cycle progression through activation of AMPK in p53 positive and
negative human hepatoma cells. Mol Nutr Food Res. 53:1156–1165.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Meena AS, Sharma A, Kumari R, Mohammad N,
Singh SV and Bhat MK: Inherent and acquired resistance to
paclitaxel in hepatocellular carcinoma: Molecular events involved.
PLoS One. 8:e615242013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hardwicke MA, Rendina AR, Williams SP,
Moore ML, Wang L, Krueger JA, Plant RN, Totoritis RD, Zhang G,
Briand J, et al: A human fatty acid synthase inhibitor binds
β-ketoacyl reductase in the keto-substrate site. Nat Chem Biol.
10:774–779. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang Z, Cappello T and Wang L: Emerging
role of microRNAs in lipid metabolism. Acta Pharm Sin B. 5:145–150.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wahdan-Alaswad RS, Cochrane DR, Spoelstra
NS, Howe EN, Edgerton SM, Anderson SM, Thor AD and Richer JK:
Metformin-induced killing of triple-negative breast cancer cells is
mediated by reduction in fatty acid synthase via miRNA-193b. Horm
Cancer. 5:374–389. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yang YQ, Qi J, Xu JQ and Hao P:
MicroRNA-142–3p, a novel target of tumor suppressor menin, inhibits
osteosarcoma cell proliferation by down-regulation of FASN. Tumour
Biol. 35:10287–10293. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cheng C, Chen ZQ and Shi XT: MicroRNA-320
inhibits osteosarcoma cells proliferation by directly targeting
fatty acid synthase. Tumour Biol. 35:4177–4183. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bhatia H, Verma G and Datta M: miR-107
orchestrates ER stress induction and lipid accumulation by
post-transcriptional regulation of fatty acid synthase in
hepatocytes. Biochim Biophys Acta. 1839:334–343. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang H, Luo QF, Peng AF, Long XH, Wang TF,
Liu ZL, Zhang GM, Zhou RP, Gao S, Zhou Y, et al: Positive feedback
regulation between Akt phosphorylation and fatty acid synthase
expression in osteosarcoma. Int J Mol Med. 33:633–639. 2014.
|
|
46
|
Li J, Huang Q, Long X, Zhang J, Huang X,
Aa J, Yang H, Chen Z and Xing J: CD147 reprograms fatty acid
metabolism in hepatocellular carcinoma cells through
Akt/mTOR/SREBP1c and P38/PPARα pathways. J Hepatol. 63:1378–1389.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang TF, Wang H, Peng AF, Luo QF, Liu ZL,
Zhou RP, Gao S, Zhou Y and Chen WZ: Inhibition of fatty acid
synthase suppresses U-2 OS cell invasion and migration via
down-regulating the activity of HER2/PI3K/AKT signaling pathway in
vitro. Biochem Biophys Res Commun. 440:229–234. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zheng SS, Gao JG, Liu ZJ, Zhang XH, Wu S,
Weng BW, Wang YL, Hou SC and Jiang B: Downregulation of fatty acid
synthase complex suppresses cell migration by targeting phospho-AKT
in bladder cancer. Mol Med Rep. 13:1845–1850. 2016.PubMed/NCBI
|
|
49
|
Chang L, Wu P, Senthilkumar R, Tian X, Liu
H, Shen X, Tao Z and Huang P: Loss of fatty acid synthase
suppresses the malignant phenotype of colorectal cancer cells by
down-regulating energy metabolism and mTOR signaling pathway. J
Cancer Res Clin Oncol. 142:59–72. 2016. View Article : Google Scholar
|
|
50
|
Li L, Pilo GM, Li X, Cigliano A, Latte G,
Che L, Joseph C, Mela M, Wang C, Jiang L, et al: Inactivation of
fatty acid synthase impairs hepatocarcinogenesis driven by AKT in
mice and humans. J Hepatol. 64:333–341. 2016. View Article : Google Scholar
|
